View in EDS

Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry

Saved in:
Bibliographic Details
Title: Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Authors: M. L. Frevert, D. Dannehl, L. Jansen, S. Hermann, H. Schäffler, S. Huwer, W. Janni, I. Juhasz-Böss, A. D. Hartkopf, F.-A. Taran
Source: Arch Gynecol Obstet
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Male, Adult, Aged, 80 and over, 0301 basic medicine, Aminopyridines, Antineoplastic Agents, Gynecologic Oncology, Middle Aged, Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms, Male/drug therapy [MeSH], monarchE, Aged, 80 and over [MeSH], Aged [MeSH], Purines [MeSH], Adult [MeSH], Humans [MeSH], Aminopyridines/therapeutic use [MeSH], OlympiA, Male breast cancer, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use [MeSH], CDK 4/6 inhibitors, Middle Aged [MeSH], Feasibility Studies [MeSH], NATALEE, Chemotherapy, Adjuvant [MeSH], Male [MeSH], Systemic therapy, Benzimidazoles/therapeutic use [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Benzimidazoles/administration, Molecular Targeted Therapy/methods [MeSH], Registries [MeSH], Breast Neoplasms, Male, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Purines, Humans, Feasibility Studies, Benzimidazoles, Registries, Molecular Targeted Therapy, Aged
Description: Background Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6 inhibitors abemaciclib, ribociclib as well as the PARP inhibitor olaparib) have recently been introduced into the treatment of high-risk early breast cancer (eBC). However, only few male patients were included in these trials (0.4%, 0.6% and 0.3%, respectively). The objective of this real-world analysis was to determine the proportion of male patients with eBC fulfilling the clinical high-risk criteria of above-mentioned trials. Patients and methods We conducted a data inquiry and analysis with the Cancer Registry of Baden-Württemberg of men with breast cancer diagnosed between January 1, 2015 and December 31, 2021. Men with eBC were identified and the number of patients at clinical high-risk according to the inclusion criteria of monarchE, NATALEE and OlympiA was assessed. Results Of 397 men with eBC, 354 (89.1%) had a HR + /Her2− and 4 (1.0%) a triple-negative subtype. 84 patients (21.2%) met the clinical high-risk criteria according to the monarchE, 189 (47.6%) those according to the NATALEE and 50 (12.6%) those according to the OlympiA trial. Conclusion In a large real-world sample, more men with eBC are at clinical high risk according to the inclusion criteria of monarchE, NATALEE and OlympiA than would be expected in women. This is most likely due to more advanced stages at initial diagnosis in men. To evaluate whether CDK4/6 and PARP inhibitors improve prognosis also in men should be the topic of future real- world analyses.
Document Type: Article
Other literature type
File Description: pdf
Language: English
ISSN: 1432-0711
DOI: 10.1007/s00404-024-07405-5
Access URL: https://pubmed.ncbi.nlm.nih.gov/38472501
https://repository.publisso.de/resource/frl:6523133
Rights: CC BY
Accession Number: edsair.doi.dedup.....52750238b0ba1504bb75f4329fae1b6f
Database: OpenAIRE
Description
Abstract:Background Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6 inhibitors abemaciclib, ribociclib as well as the PARP inhibitor olaparib) have recently been introduced into the treatment of high-risk early breast cancer (eBC). However, only few male patients were included in these trials (0.4%, 0.6% and 0.3%, respectively). The objective of this real-world analysis was to determine the proportion of male patients with eBC fulfilling the clinical high-risk criteria of above-mentioned trials. Patients and methods We conducted a data inquiry and analysis with the Cancer Registry of Baden-Württemberg of men with breast cancer diagnosed between January 1, 2015 and December 31, 2021. Men with eBC were identified and the number of patients at clinical high-risk according to the inclusion criteria of monarchE, NATALEE and OlympiA was assessed. Results Of 397 men with eBC, 354 (89.1%) had a HR + /Her2− and 4 (1.0%) a triple-negative subtype. 84 patients (21.2%) met the clinical high-risk criteria according to the monarchE, 189 (47.6%) those according to the NATALEE and 50 (12.6%) those according to the OlympiA trial. Conclusion In a large real-world sample, more men with eBC are at clinical high risk according to the inclusion criteria of monarchE, NATALEE and OlympiA than would be expected in women. This is most likely due to more advanced stages at initial diagnosis in men. To evaluate whether CDK4/6 and PARP inhibitors improve prognosis also in men should be the topic of future real- world analyses.
ISSN:14320711
DOI:10.1007/s00404-024-07405-5